Discussion on the Evaluation of New Traditional Chinese Medicine in Line with the Characteristics of TCM

Sun Yu

Chinese Pharmaceutical Affairs ›› 2020, Vol. 34 ›› Issue (7) : 749-753.

Chinese Pharmaceutical Affairs ›› 2020, Vol. 34 ›› Issue (7) : 749-753. DOI: 10.16153/j.1002-7777.2020.07.003
Supervision Administration

Discussion on the Evaluation of New Traditional Chinese Medicine in Line with the Characteristics of TCM

  • Sun Yu
Author information +
History +

Abstract

Objective: To discuss the evaluation of new traditional Chinese medicines (TCM) which differ from new chemical drugs. Methods: The evaluation idea of new TCM was innovated by using the tool of the realworld evidence (RWE), the method of overall evidence evaluation, and the technical support of the electronic patient-reported outcome (PRO). Results: 1) This article put forward the idea of quality consistency evaluation in the quality control of new TCM. Under the premise of unsatisfactory evaluation of the quality consistency of new TCM in a single angle, the multi-angle review concept of the overall evidence method was used to evaluate the consistency of the efficacy of multiple batches of drugs with RWE, and to appropriately relax the requirements on consistency of the quality of new TCM. It was required to make the consistency evaluation of the efficacy of new TCM as a powerful supplement to the quality consistency evaluation. 2) The idea of clinical efficacy evaluation of new TCM was proposed. Based on the evaluation of traditional clinical trials, the patient-focused clinical trial design was conduted to create electronic PRO, focus on improving the life quality of patients and form supporting evidence for clinical efficacy. Conclusion: To encourage the use of new tools, new methods, new technologies, new ideas, fully embody the pioneering nature of TCM clinical efficacy evaluation methods in the evaluation of new TCM, and innovate the evaluation ideas of new TCM.

Key words

real-world evidence (RWE); clinical evaluation of the new TCM; quality/effect consistency; overall evidence evaluation; patient-reported outcome (PRO)

Cite this article

Download Citations
Sun Yu. Discussion on the Evaluation of New Traditional Chinese Medicine in Line with the Characteristics of TCM[J]. Chinese Pharmaceutical Affairs, 2020, 34(7): 749-753 https://doi.org/10.16153/j.1002-7777.2020.07.003

References

[1] 中国科学技术协会.中国科协发布2019重大科学问题和工程技术难题[EB/OL].(2019-06-30)[2019-10-14].https://baijiahao.baidu.com/s?id=1637749188054865430& wfr=spider&for=pc.
[2] 国家药品监督管理局药品审评中心.关于公开征求《真实世界证据支持药物研发的基本考虑》意见的通知 [EB/OL].(2019-05-29)[2019-10-14].http://www.cde.org.cn/news.do?method=largeInfo&id=314865.
[3] 日本汉方生药制剂协会.2040年中医药的未来愿景 [EB/OL].(2018-07-01)[2019-10-14].https://www.nikkankyo.org/action/pdf/vision2040.pdf.
[4] Wing L,Yongshen R,Fulan G,et al.Mechanism Based Quality Control(MBQC)of Herbal Products:A Case Study YIV-906(PHY906)[J].Frontiers in Pharmacology,2018,9:1324-1330.
[5] Ram S,Sau L L,Amy R,et al.The Science and Regulations of Naturally Derived Complex Drugs[M].Switzerland:Springer,2019.
[6] Melanie J C,Daniel J O'C,Ethan M B.Harnessing the Patient Voice in Real-world Evidence:The Essential Role of Patient-reported Outcomes[J/OL].(2019-05-15)[2019-10-14].https://www.nature.com/magazine-assets/d41573-019-00088-7/d41573-019-00088-7.pdf.
[7] U.S.Food & Drug Administration.Framework for FDA’s Real-World Evidence Program[EB/OL].(2018-12-01)[2019-10-14].https://www.fda.gov/media/120060/download.
[8] Qi L,Anuradha R,Shiew-Mei H.Real-World Data and Clinical Pharmacology:A Regulatory Science Perspective [J].Clinical Pharmacology & Therapeutics,2019,106(1):67-71.

24

Accesses

0

Citation

Detail

Sections
Recommended

/